




RealRate

PHARMACEUTICAL 2018

ARATANA THERAPEUTICS INC.
Rank 135 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

ARATANA THERAPEUTICS INC. Rank 135 of 349

The relative strengths and weaknesses of ARATANA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARATANA THERAPEUTICS INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 84% points. The greatest weakness of ARATANA THERAPEUTICS INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -104%, being 173% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	85,239
Cost of Goods Sold	0
Intangible Assets	47,911
Liabilities, Current	35,496
Liabilities, Non-Current	70
Other Assets	876
Other Compr. Net Income	2,777
Other Expenses	26,006
Other Liabilities	19,492
Other Net Income	-3,054
Property and Equipment	1,166
Research and Development	15,126
Revenues	25,573
Selling, General and Administrative Expense	28,897

Output Variable	Value in 1000 USD
Assets	135,192
Liabilities	55,058
Expenses	70,029
Stockholders Equity	80,134
Net Income	-47,510
Comprehensive Net Income	-46,122
Economic Capital Ratio	-104%

